CA3022673A1 - Tau immunotherapy - Google Patents
Tau immunotherapy Download PDFInfo
- Publication number
- CA3022673A1 CA3022673A1 CA3022673A CA3022673A CA3022673A1 CA 3022673 A1 CA3022673 A1 CA 3022673A1 CA 3022673 A CA3022673 A CA 3022673A CA 3022673 A CA3022673 A CA 3022673A CA 3022673 A1 CA3022673 A1 CA 3022673A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- seq
- tau
- constant region
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662330786P | 2016-05-02 | 2016-05-02 | |
| US62/330,786 | 2016-05-02 | ||
| PCT/IB2017/052543 WO2017191559A1 (en) | 2016-05-02 | 2017-05-02 | Tau immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3022673A1 true CA3022673A1 (en) | 2017-11-09 |
Family
ID=58709514
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3022673A Pending CA3022673A1 (en) | 2016-05-02 | 2017-05-02 | Tau immunotherapy |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10752679B2 (https=) |
| EP (1) | EP3452507B1 (https=) |
| JP (2) | JP7170316B2 (https=) |
| KR (1) | KR102506091B1 (https=) |
| CN (1) | CN109415432B (https=) |
| CA (1) | CA3022673A1 (https=) |
| DK (1) | DK3452507T3 (https=) |
| ES (1) | ES2933491T3 (https=) |
| FI (1) | FI3452507T3 (https=) |
| HU (1) | HUE060258T2 (https=) |
| PL (1) | PL3452507T3 (https=) |
| PT (1) | PT3452507T (https=) |
| WO (1) | WO2017191559A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2902026C (en) | 2013-03-13 | 2023-08-29 | Prothena Biosciences Limited | Tau immunotherapy |
| PE20190208A1 (es) | 2016-05-02 | 2019-02-07 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau |
| EP3452507B1 (en) * | 2016-05-02 | 2022-10-19 | Prothena Biosciences Limited | Tau immunotherapy |
| CA3022515A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
| BR112019017021A2 (pt) | 2017-02-17 | 2020-04-14 | Denali Therapeutics Inc | anticorpos anti-tau e métodos de uso dos mesmos |
| CN110881274B (zh) | 2017-05-02 | 2024-11-15 | 普罗塞纳生物科学有限公司 | 识别tau的抗体 |
| EP3935083A4 (en) * | 2019-03-03 | 2022-11-30 | Prothena Biosciences Limited | Antibodies recognizing tau |
| WO2020227515A1 (en) | 2019-05-07 | 2020-11-12 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
| CN114174515A (zh) * | 2019-05-27 | 2022-03-11 | 英属哥伦比亚大学 | tau中的构象特异性表位、其抗体和其相关方法 |
| WO2021236809A2 (en) | 2020-05-19 | 2021-11-25 | Othair Prothena Limited | Multi-epitope vaccine for the treatment of alzheimer's disease |
| KR20230080397A (ko) | 2020-08-07 | 2023-06-07 | 오타이르 프로테나 리미티드 | 알츠하이머 질환을 치료하기 위한 멀티에피토프 백신 |
| CA3218876A1 (en) * | 2021-05-21 | 2022-11-24 | Agency For Science, Technology And Research | Anti-ceacam5/6 antigen-binding molecules and methods of treatment thereof |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| CA3266790A1 (en) | 2022-09-15 | 2024-03-21 | Voyager Therapeutics, Inc. | TAU PROTEIN BINDING COMPOUNDS |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
Family Cites Families (138)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US101A (en) | 1836-12-06 | Method of jcakibtg and furling iw sails fob ships | ||
| US5530A (en) | 1848-04-25 | Horse-power | ||
| US5208036A (en) | 1985-01-07 | 1993-05-04 | Syntex (U.S.A.) Inc. | N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| AU701578B2 (en) | 1992-08-21 | 1999-02-04 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| WO1994012629A1 (en) | 1992-12-02 | 1994-06-09 | Baylor College Of Medicine | Episomal vectors for gene therapy |
| DE69318420T2 (de) | 1992-12-14 | 1999-01-28 | Naamloze Vennootschap Innogenetics S.A., Gent | Monoklonale antikörper gegen das mikrotubulusassoziierte tauprotein,hybridomen, die diese antikörper sezernieren, antigenerkennung durch diese monoklonalen antikörper und deren verwendung |
| AU698962B2 (en) | 1993-09-14 | 1998-11-12 | Epimmune, Inc. | Alteration of immune response using pan DR-binding peptides |
| US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| US7427392B1 (en) | 1994-11-14 | 2008-09-23 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau |
| US7153510B1 (en) | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
| DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| AU753688B2 (en) | 1997-03-10 | 2002-10-24 | Ottawa Civic Loeb Research Institute | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| WO2000046750A1 (en) | 1999-02-05 | 2000-08-10 | Samsung Electronics Co., Ltd. | Image texture retrieving method and apparatus thereof |
| AT500379B8 (de) | 2001-02-02 | 2009-08-15 | Axon Neuroscience | Tau-proteine |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| ES2352668T3 (es) | 2002-08-14 | 2011-02-22 | Mitsubishi Chemical Medience Corporation | Anticuerpo específico para una proteína tau del sistema nervioso central. |
| KR101149777B1 (ko) | 2002-11-29 | 2012-06-11 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | 신규한 네오마이신 포스포트랜스퍼라제 유전자 및 고생산성 재조합 세포의 선별 방법 |
| US7847146B2 (en) | 2003-03-28 | 2010-12-07 | Baylor College Of Medicine | Model for neurodegenerative disorders |
| DE10338531A1 (de) | 2003-08-19 | 2005-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Reklonierung von Produktionszellen |
| US20050132424A1 (en) | 2003-10-21 | 2005-06-16 | Envivo Pharmaceuticals, Inc. | Transgenic flies expressing Abeta42-Dutch |
| AU2005291486A1 (en) | 2004-10-01 | 2006-04-13 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Novel antibodies directed to the mammalian EAG1 ion channel protein |
| WO2006051065A2 (en) | 2004-11-10 | 2006-05-18 | Boehringer Ingelheim Pharma Gmbh & Co.Kg | Use of flow-cytometric analysis to optimize cell banking strategies for cho cells |
| CA2591665C (en) | 2004-12-20 | 2015-05-05 | Crucell Holland B.V. | Binding molecules capable of neutralizing west nile virus and uses thereof |
| US7855276B2 (en) | 2004-12-30 | 2010-12-21 | The United States Of America As Represented By The Department Of Health And Human Services | Framework residue substituted humanized COL-1 antibodies and their use |
| US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| EP2028932A4 (en) | 2006-06-16 | 2011-10-12 | Vitruvean Llc | TAU AND AMYLOID FOREIGNER FRAGMENT EXPRESSING TRANSGENIC FLY |
| CA2655379A1 (en) | 2006-06-22 | 2007-12-27 | Walter And Eliza Hall Institute Of Medical Research | Structure of the insulin receptor ectodomain |
| US20080124760A1 (en) | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
| WO2008022153A2 (en) | 2006-08-14 | 2008-02-21 | The Regents Of The University Of California | Inhibitors of pde4 and methods of use |
| KR101552735B1 (ko) | 2006-12-01 | 2015-09-14 | 메다렉스, 엘.엘.시. | 씨디22에 결합하는 인간 항체 및 이의 용도 |
| PL2118300T3 (pl) | 2007-02-23 | 2015-11-30 | Prothena Biosciences Ltd | Zapobieganie i leczenie synukleinopatii i amyloidozy |
| EP2522729A1 (en) | 2007-03-02 | 2012-11-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Improvement of protein production |
| EP2031064A1 (de) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
| JP2009056790A (ja) | 2007-09-03 | 2009-03-19 | Takao Otogawa | ファイル用ポケット |
| TW200927761A (en) | 2007-09-26 | 2009-07-01 | U3 Pharma Ag | Heparin-binding epidermal growth factor-like growth factor antigen binding proteins |
| US9272030B2 (en) | 2007-10-17 | 2016-03-01 | Janssen Sciences Ireland Uc | Use of tau to monitor immunotherapy |
| UA104132C2 (en) | 2007-11-13 | 2014-01-10 | Тева Биофармасьютикалз Юесей, Инк. | Humanized antibodies against tl1a |
| CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
| JP2010014691A (ja) | 2008-06-20 | 2010-01-21 | Igaku Seibutsugaku Kenkyusho:Kk | 腹水中のメソテリン及び／又は巨核球増強因子を検出するための方法、キット、試薬及び装置 |
| JP5685535B2 (ja) | 2008-08-18 | 2015-03-18 | ファイザー インコーポレイティッド | Ｃｃｒ２に対する抗体 |
| US9605054B2 (en) | 2009-02-23 | 2017-03-28 | The Board Of Trustees Of The University Of Illinois | Composition and method for treating a tauopathy |
| EP2998405B1 (en) | 2009-05-13 | 2019-12-11 | Genzyme Corporation | Anti-human cd52 immunoglobulins |
| CA3239368A1 (en) | 2009-06-10 | 2010-12-16 | New York University | Immunological targeting of pathological tau proteins |
| US20110045534A1 (en) | 2009-08-20 | 2011-02-24 | Cell Signaling Technology, Inc. | Nucleic Acid Cassette For Producing Recombinant Antibodies |
| EP2470211B1 (en) | 2009-08-28 | 2016-01-27 | The Board of Regents of The University of Texas System | Antibodies that bind tau oligomers |
| WO2011053565A2 (en) | 2009-10-29 | 2011-05-05 | Biomedical Sciences Research Centre "Alexander Fleming" | Compositions and methods for detecting a tauopathy |
| WO2011075636A2 (en) | 2009-12-18 | 2011-06-23 | Amgen Inc. | Wise binding agents and epitopes |
| EP2522360B1 (en) | 2010-01-08 | 2016-11-16 | Kyoto University | Vaccine for treatment of tauopathy |
| TWI429453B (zh) | 2010-02-23 | 2014-03-11 | 建南德克公司 | 抗tat419抗體及其用途 |
| JP2011201655A (ja) | 2010-03-25 | 2011-10-13 | Minoru Industrial Co Ltd | ダンボールテープ貼付機 |
| ES2684475T3 (es) | 2010-04-15 | 2018-10-03 | Abbvie Inc. | Proteínas que se unen a beta amiloide |
| ITRM20100320A1 (it) | 2010-06-11 | 2011-12-11 | Consiglio Nazionale Ricerche | Metodo per la diagnostica e il trattamento delle taupatie |
| US20120023911A1 (en) | 2010-07-28 | 2012-02-02 | Gm Global Technology Operations, Inc. | Detection of exhaust particulate filter substrate failure |
| BR112013008765B8 (pt) | 2010-10-11 | 2023-05-02 | Biogen Idec Int Neuroscience Gmbh | Anticorpos monoclonais anti-tau humano isolados ou um fragmento de ligação à tau dos mesmos, métodos de preparação dos mesmos, polinucleotídeo ou polinucleotídeos, vetor ou vetores, composição, método in vitro de diagnóstico ou monitoramento da progressão de uma tauopatia neurodegenerativa em um indivíduo humano, método in vitro para diagnosticar uma tauopatia neurodegenerativa em um indivíduo humano, e kit útil para o diagnóstico de uma tauopatia neurodegenerativa |
| EP2673635A4 (en) | 2011-02-07 | 2015-08-12 | Neotope Biosciences Ltd | IMMUNOTHERAPY THROUGH APOE |
| WO2012149365A2 (en) | 2011-04-27 | 2012-11-01 | Northwestern University | Antibodies selective for pathological tau dimers and prefibrillar pathological tau oligomers and their uses in treatment, diagnosis and monitoring of tauopathies |
| GB201109238D0 (en) | 2011-06-01 | 2011-07-13 | Antitope Ltd | Antibodies |
| GB201111361D0 (en) | 2011-07-04 | 2011-08-17 | Nordic Bioscience As | Biochemical markers for neurodegenerative conditions |
| GB201112056D0 (en) | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
| US9505847B2 (en) | 2011-08-22 | 2016-11-29 | Cnj Holdings Inc | Clostridium difficile antibodies |
| ES2656442T3 (es) | 2011-09-19 | 2018-02-27 | Axon Neuroscience Se | Terapia basada en proteínas y diagnóstico de una patología mediada por tau en la enfermedad de Alzheimer |
| TW201817744A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| RU2639537C2 (ru) | 2011-10-07 | 2017-12-21 | Ац Иммуне С.А. | Фосфоспецифичные антитела, распознающие тау |
| US9738709B2 (en) | 2011-10-21 | 2017-08-22 | Ohio State Innovation Foundation | Methylated peptides derived from tau protein and their antibodies for diagnosis and therapy of alzheimer's disease |
| RS57413B1 (sr) | 2012-03-28 | 2018-09-28 | Sanofi Sa | Antitela za ligande bradikinin b1 receptora |
| JP6293731B2 (ja) | 2012-04-05 | 2018-03-14 | エーシー イミューン エス．エー． | ヒト化タウ抗体 |
| US9428864B2 (en) | 2012-04-18 | 2016-08-30 | E I Du Pont De Nemours And Company | Multilayered sheet |
| DE102012211455A1 (de) | 2012-07-02 | 2014-01-02 | Wobben Properties Gmbh | Handhabungsvorrichtung zum Handhaben einer Rotorblattform zum Fertigen eines Rotorblattes einer Windenergieanlage |
| HK1209768A1 (en) | 2012-07-03 | 2016-04-08 | Washington University | Antibodies to tau |
| PE20150646A1 (es) | 2012-08-16 | 2015-05-21 | Ipierian Inc | Metodos de tratamiento de una tauopatia |
| US20140056901A1 (en) | 2012-08-21 | 2014-02-27 | The Institute For Molecular Medicine | Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies |
| WO2014059442A2 (en) | 2012-10-12 | 2014-04-17 | Arizona Board Agents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | Antibody based reagents that specifically recognize toxic oligomeric forms of tau |
| US9200068B2 (en) | 2012-12-18 | 2015-12-01 | Regents Of The University Of Minnesota | Compositions and methods related to tauopathy |
| PT2935326T (pt) | 2012-12-21 | 2020-09-14 | Biogen Ma Inc | Anticorpos anti-tau humanos |
| US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| US9364191B2 (en) | 2013-02-11 | 2016-06-14 | University Of Rochester | Method and apparatus of spectral differential phase-contrast cone-beam CT and hybrid cone-beam CT |
| CA2902026C (en) | 2013-03-13 | 2023-08-29 | Prothena Biosciences Limited | Tau immunotherapy |
| CA2939692C (en) | 2013-03-15 | 2022-10-18 | The Trustees Of The University Of Pennsylvania | Blood biomarkers that predict persistent cognitive dysfunction after concussion |
| EP2968548B1 (en) | 2013-03-15 | 2020-09-09 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
| CA2921805C (en) | 2013-08-22 | 2023-03-07 | Acceleron Pharma, Inc. | Tgf-beta receptor type ii variants and uses thereof |
| EP3074420A2 (en) | 2013-11-27 | 2016-10-05 | Ipierian, Inc. | Methods of treating a tauopathy |
| JP2017505756A (ja) | 2013-12-13 | 2017-02-23 | ザ ジェネラル ホスピタル コーポレイション | 可溶性高分子量（ｈｍｗ）タウ種およびその用途 |
| UA129760C2 (uk) | 2013-12-17 | 2025-07-30 | Дженентек, Інк. | Анти-cd3 антитіло та спосіб його застосування |
| US9629801B2 (en) | 2014-01-10 | 2017-04-25 | Wisconsin Alumni Research Foundation | Blood-brain barrier targeting antibodies |
| US20150253341A1 (en) | 2014-02-10 | 2015-09-10 | Merck Sharp & Dohme Corp. | Quantification of tau in biological samples by immunoaffinity enrichment and mass spectrometry |
| WO2015197820A1 (en) | 2014-06-26 | 2015-12-30 | Crucell Holland B.V. | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
| TWI664190B (zh) | 2014-06-27 | 2019-07-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗－ｔａｕ抗體 |
| SI3221349T1 (sl) | 2014-11-19 | 2021-02-26 | Axon Neuroscience Se | Humanizirano tau protitelo pri alzheimerjevi bolezni |
| CA2874083C (en) | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| US10202444B2 (en) | 2015-02-24 | 2019-02-12 | Rpeptide, Llc | Anti-tau antibodies |
| EP4465050A3 (en) | 2015-06-05 | 2025-06-11 | Genentech, Inc. | Anti-tau antibodies and methods of use |
| WO2016201434A2 (en) | 2015-06-12 | 2016-12-15 | C2N Diagnostics, Llc | Stable formulations of humanized anti-tau antibody |
| CA2991264C (en) | 2015-07-06 | 2023-10-10 | Ucb Biopharma Sprl | Tau-binding antibodies |
| JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| US11327080B2 (en) | 2015-07-21 | 2022-05-10 | BioArctic Neruoscience AB | Method for treatment of traumatic brain injury targeting aggregated peptides |
| AU2016334051B2 (en) | 2015-10-06 | 2023-10-26 | Alector Llc | Anti-TREM2 antibodies and methods of use thereof |
| PE20190208A1 (es) | 2016-05-02 | 2019-02-07 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau |
| EP3452507B1 (en) | 2016-05-02 | 2022-10-19 | Prothena Biosciences Limited | Tau immunotherapy |
| CA3022515A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
| US10947302B2 (en) | 2016-11-04 | 2021-03-16 | The Regents Of The University Of California | Compositions targeting 3-repeat tau for the treatment of neurodegenerative disorders, and methods for making and using them |
| CN117820467A (zh) | 2016-12-07 | 2024-04-05 | 基因泰克公司 | 抗tau抗体和使用方法 |
| MA48595A (fr) | 2016-12-07 | 2020-03-18 | Ac Immune Sa | Anticorps anti-tau et leurs méthodes d'utilisation |
| BR112019017021A2 (pt) | 2017-02-17 | 2020-04-14 | Denali Therapeutics Inc | anticorpos anti-tau e métodos de uso dos mesmos |
| JP7165995B2 (ja) | 2017-02-21 | 2022-11-07 | アールイーエムディー バイオセラピューティクス，インコーポレイテッド | 細胞傷害性ｔリンパ球抗原－４（ｃｔｌａ－４）に結合する抗体を使用した癌治療 |
| TWI771389B (zh) | 2017-03-16 | 2022-07-21 | 美商健生生物科技公司 | 抗phf-tau抗體及其用途 |
| KR20190133162A (ko) | 2017-03-28 | 2019-12-02 | 제넨테크, 인크. | 신경퇴행성 질병의 치료 방법 |
| WO2018178077A1 (en) | 2017-03-28 | 2018-10-04 | Janssen Vaccines & Prevention B.V. | Binding molecules that specifically bind to tau |
| CN110881274B (zh) | 2017-05-02 | 2024-11-15 | 普罗塞纳生物科学有限公司 | 识别tau的抗体 |
| MX2019015071A (es) | 2017-06-16 | 2020-02-13 | Bristol Myers Squibb Co | Composiciones y metodos para tratar tauopatias. |
| EP3697814A1 (en) | 2017-10-16 | 2020-08-26 | Eisai R&D Management Co., Ltd. | Anti-tau antibodies and uses thereof |
| EP3706795A4 (en) | 2017-11-09 | 2021-10-13 | Pinteon Therapeutics Inc. | METHODS AND COMPOSITIONS FOR GENERATING AND USING HUMANIZED CONFORMATION SPECIFIC PHOSPHORYLATED TAU ANTIBODIES |
| WO2019110571A1 (en) | 2017-12-04 | 2019-06-13 | Janssen Vaccines & Prevention B.V. | Binding molecules that specifically bind to tau |
| CN112004827A (zh) | 2018-03-23 | 2020-11-27 | 艾伯维德国有限责任两合公司 | 稳定的水性抗tau抗体调配物 |
| WO2019186276A2 (en) | 2018-03-28 | 2019-10-03 | Axon Neuroscience Se | Antibody-based methods of detecting and treating alzheimer's disease |
| US20210230255A1 (en) | 2018-04-27 | 2021-07-29 | Fondazione Ebri Rita Levi-Montalcini | Antibody directed against a tau-derived neurotoxic peptide and uses thereof |
| SG11202104549TA (en) | 2018-11-08 | 2021-05-28 | Prothena Biosciences Ltd | Antibodies recognizing tau |
| CA3118818A1 (en) | 2018-11-08 | 2020-05-14 | Prothena Biosciences Limited | Antibodies recognizing tau |
| US20220273779A1 (en) | 2018-11-19 | 2022-09-01 | The Board Of Regents Of The University Of Texas System | Tau peptide antigens and antibodies binding thereto for the treatment of tauopathies |
| WO2020163817A1 (en) | 2019-02-08 | 2020-08-13 | Prothena Biosciences Limited | Antibodies recognizing tau |
| FR3092834B1 (fr) | 2019-02-15 | 2021-09-24 | Biorengaz | Support de culture pour procédé méthanisation |
| EP3935083A4 (en) | 2019-03-03 | 2022-11-30 | Prothena Biosciences Limited | Antibodies recognizing tau |
| CN113631573B (zh) | 2019-03-25 | 2024-06-04 | 国家医疗保健研究所 | 抗Tau抗体及其在制备用于治疗疾病的药物中的用途 |
| CN114430744B (zh) | 2019-07-15 | 2024-06-21 | 阿德尔公司 | 抗Tau抗体及其用途 |
-
2017
- 2017-05-02 EP EP17723767.4A patent/EP3452507B1/en active Active
- 2017-05-02 FI FIEP17723767.4T patent/FI3452507T3/fi active
- 2017-05-02 US US16/092,439 patent/US10752679B2/en active Active
- 2017-05-02 PL PL17723767.4T patent/PL3452507T3/pl unknown
- 2017-05-02 PT PT177237674T patent/PT3452507T/pt unknown
- 2017-05-02 JP JP2018556995A patent/JP7170316B2/ja active Active
- 2017-05-02 KR KR1020187034424A patent/KR102506091B1/ko active Active
- 2017-05-02 DK DK17723767.4T patent/DK3452507T3/da active
- 2017-05-02 ES ES17723767T patent/ES2933491T3/es active Active
- 2017-05-02 HU HUE17723767A patent/HUE060258T2/hu unknown
- 2017-05-02 CN CN201780038954.3A patent/CN109415432B/zh active Active
- 2017-05-02 CA CA3022673A patent/CA3022673A1/en active Pending
- 2017-05-02 WO PCT/IB2017/052543 patent/WO2017191559A1/en not_active Ceased
-
2020
- 2020-07-20 US US16/933,792 patent/US11492393B2/en active Active
-
2022
- 2022-05-24 JP JP2022084267A patent/JP7405459B2/ja active Active
- 2022-09-30 US US17/937,109 patent/US12195525B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2933491T3 (es) | 2023-02-09 |
| KR102506091B1 (ko) | 2023-03-07 |
| DK3452507T3 (da) | 2022-11-14 |
| HUE060258T2 (hu) | 2023-02-28 |
| CN109415432B (zh) | 2022-07-08 |
| CN109415432A (zh) | 2019-03-01 |
| JP2022116136A (ja) | 2022-08-09 |
| JP2019521649A (ja) | 2019-08-08 |
| US10752679B2 (en) | 2020-08-25 |
| EP3452507B1 (en) | 2022-10-19 |
| FI3452507T3 (fi) | 2022-12-15 |
| KR20190015705A (ko) | 2019-02-14 |
| US11492393B2 (en) | 2022-11-08 |
| WO2017191559A1 (en) | 2017-11-09 |
| US20230126858A1 (en) | 2023-04-27 |
| US12195525B2 (en) | 2025-01-14 |
| JP7170316B2 (ja) | 2022-11-14 |
| JP7405459B2 (ja) | 2023-12-26 |
| PT3452507T (pt) | 2022-12-20 |
| PL3452507T3 (pl) | 2023-01-09 |
| US20210032319A1 (en) | 2021-02-04 |
| US20190322728A1 (en) | 2019-10-24 |
| EP3452507A1 (en) | 2019-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230340094A1 (en) | Tau Immunotherapy | |
| US12195525B2 (en) | Tau immunotherapy | |
| JP7843068B2 (ja) | タウを認識する抗体 | |
| CA3022515A1 (en) | Antibodies recognizing tau | |
| CA2825791A1 (en) | Apoe immunotherapy | |
| HK40035741A (en) | Tau immunotherapy | |
| HK40002250A (en) | Tau immunotherapy | |
| HK40002250B (en) | Tau immunotherapy | |
| HK1217337B (en) | Tau immunotherapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220426 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240806 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241128 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250203 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250402 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250402 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250603 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250603 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251117 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260316 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260325 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260325 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260325 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260401 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260401 |